SC
TEVA icon

Savant Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Savant Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
+11,747
New +$391K ﹤0.01% 1370

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Savant Capital's TEVA Position: Q2 2026 in Review

Savant Capital opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 11,747 shares worth $378K. The stake represents ﹤0.01% of the portfolio and ranks #1370 among its holdings.

672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Savant Capital held 11,747 shares of Teva Pharmaceuticals worth $378K as of Q2 2026.
  • Teva Pharmaceuticals was a new Savant Capital position in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1370 holding.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.